At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Acoustic Cluster Therapy (combination product), Modified FOLFIRINOX (drug)
- How long the study runs
- Study runs about 25 months (dates as stated)
- About the drug or intervention
- Acoustic Cluster Therapy — combination product: Drug: PS101; Device: Ultrasound · Modified FOLFIRINOX — drug: Chemotherapy
- Patient visit burden
- Not specified by the sponsor
In plain English
This trial is testing a treatment called Acoustic Cluster Therapy (ACT) given together with chemotherapy for people with locally advanced pancreatic cancer. This is a type of pancreatic cancer that has grown into nearby tissue and cannot be removed with surgery. The trial is paid for by a company called EXACT Therapeutics AS.
Who can take part
- Doctors have decided that surgery to try to cure your cancer is not suitable for you, and scans and tissue tests show pancreatic cancer that cannot be operated on, or is 'borderline' (doctors are unsure if an operation could remove it).
- The study doctor believes you are well enough to have chemotherapy with a combination of drugs called mFOLFIRINOX.
Who may not be able to
- You have already had any cancer treatment for your pancreatic cancer, such as chemotherapy, surgery or radiotherapy. (An operation to ease symptoms, called a bypass, and a small tube called a stent placed in the bile duct are still allowed.)
What taking part involves
- • A treatment called Acoustic Cluster Therapy (ACT).
- • Chemotherapy using a combination of drugs called mFOLFIRINOX.
- • These two treatments are given together.
Time commitment: Not stated — ask the trial team about hospital visits, how long the trial lasts, and what taking part involves.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 25
- Started
- 2025-06-19
- Last checked
- 2026-03
Plain English Summary
What is this study?
- • Testing a new treatment for locally advanced pancreatic adenocarcinoma
- • Phase2 - 25 participants
- • The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with locally advanced pancreatic adenocarcinoma
Where?
- • Cambridge - CAMBRIDGE CANCER TRIALS CENTRE-Addenbrooke's Hospital
- • Hammersmith - Gary Weston Centre- Imperial College Healthcare- Du Cane Road
- • Sutton - The Royal Marsden- Downs Road
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer.
More detail
Patients with Locally Advanced Pancreatic Cancer who have not received prior treatment to their pancreatic cancer will receive ACT treatment (the drug PS101 and ultrasound application to the tumor) with up to eight 2-week cycles of modified FOLFIRINOX chemotherapy. ACT treatment will be given on Day 1 of each cycle of chemotherapy. Patients' well-being and side effects will be assessed at the same visits. The objective efficacy of the treatment will be assessed by CT scans every 8 weeks.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Not deemed suitable for primary curative surgery and have radiographic and pathological disease consistent with...
- ✓Suitable to receive treatment with mFOLFIRINOX according to the Investigator's assessment.
Who cannot take part
- ✗Any prior anti-cancer treatment for pancreatic cancer (e.g. drug treatment, surgery, radiation). Palliative bypass...
See the full criteria
Where Is This Study? (3 UK sites)
CAMBRIDGE CANCER TRIALS CENTRE-Addenbrooke's Hospital
Cambridge CB2 0QQ, United Kingdom
Gary Weston Centre- Imperial College Healthcare- Du Cane Road
Hammersmith W12 0HS, United Kingdom
The Royal Marsden- Downs Road
Sutton SM2 5PT, United Kingdom